GlassScriptPhysician profile
Richard A Caputo
NPI 1528062007
$4,115.72
in general payments reported to CMS, 2019-2025
21 companies · $807 in 2025
The $807 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $776 · 2020: $327 · 2021: $402 · 2022: $572 · 2023: $611 · 2024: $620 · 2025: $807.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,010 · Education: $28.66.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,010.30 |
| Education | $28.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $765.35 | 2019-2024 | Lokelma, Farxiga |
| Novo Nordisk INC | $637.57 | 2023-2025 | Ozempic, Wegovy, Rybelsus |
| Esperion Therapeutics, INC. | $375.57 | 2024-2025 | Nexletol |
| Amgen INC. | $372.68 | 2019-2025 | Repatha, Repatha, Otezla |
| Otsuka America Pharmaceutical, INC. | $358.05 | 2019-2025 | Jynarque |
| Novartis Pharmaceuticals Corporation | $354.90 | 2022-2025 | |
| Mallinckrodt Enterprises LLC | $263.60 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $203.40 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $150.00 | 2022 | |
| Mallinckrodt Hospital Products INC. | $145.60 | 2020-2025 | Acthar, Terlivaz |
| Sanofi-Aventis U.S. LLC | $119.64 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $109.70 | 2019-2021 | |
| Vifor Pharma, INC. | $84.48 | 2022-2024 | Veltassa |
| Horizon Therapeutics Plc | $33.53 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $29.05 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $28.66 | 2025 | Filspari |
| Daiichi Sankyo INC. | $18.94 | 2019 | |
| Corcept Therapeutics | $18.04 | 2021 | |
| Fresenius USA Marketing, INC. | $17.54 | 2019 | |
| Currax Pharmaceuticals LLC | $15.76 | 2023 | Contrave |
| Shire North American Group INC | $13.66 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Caputo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.